RLYB – rallybio corporation (US:NASDAQ)
Stock Stats
News
Rallybio Announces Initiation of Phase 2 Clinical Trial of RLYB212 [Yahoo! Finance]
Rallybio Announces Initiation of Phase 2 Clinical Trial of RLYB212
Rallybio Co. (NASDAQ: RLYB) had its price target lowered by analysts at HC Wainwright from $6.00 to $5.00. They now have a "buy" rating on the stock.
Rallybio Reports Third Quarter 2024 Financial Results and Provides Business Updates
Rallybio Co. (NASDAQ: RLYB) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $6.00 price target on the stock.
Form SC 13G/A Rallybio Corp Filed by: FMR LLC
Form 10-Q Rallybio Corp For: Sep 30
Form 8-K Rallybio Corp For: Nov 07
Form 8-K Rallybio Corp For: Sep 16
Top News Gainers
Top News Decliners
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.